For the first time, researchers have isolated a subtype of gamma-delta T-cells that offers protection in women with triple-negative breast cancer.
A new combination may help with overall and progression-free survival in liver cancer.
A recent report highlighted the progress made globally in preventing cancer. However, improvements are still needed.
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients.
There could be a new way to diagnose brain tumors earlier.
The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.
Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
The agent has a high affinity and specificity for interleukin-1 beta.